3 Visa and Citizen Services Company, Engines and Power Generation Company and Pharmaceutical Company Stocks With a Strong Future Roadmap: BLS International Services, Cummins India and Emcure Pharmaceuticals
- November 11, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
BLS International Services, Cummins India and Emcure Pharmaceuticals: ROE of 18.7% to 27.9% and FY22 to FY26 revenue CAGR of 12.1% to 37.5%. Prices as of 10 Nov 2026.
Quick Answer
The three visa services, power engine and pharma stocks to watch are BLS International Services, Cummins India and Emcure Pharmaceuticals. Their return on equity ranges from 18.7% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.1% to 37.5%. BLS International Services leads on both return on equity at 27.9% and revenue growth at 37.5% a year. Prices are based on the 10 November 2026 close, and this article is educational, not investment advice.
Visa services, power engine and pharma stocks offer a focused view of a sector where demand keeps widening. BLS International Services, Cummins India and Emcure Pharmaceuticals cover a visa and citizen services company, an engines and power generation company and a pharmaceutical company.
This list covers three visa services, power engine and pharma stocks with complete current figures: BLS International Services, Cummins India and Emcure Pharmaceuticals. Every figure comes from the latest reported financials and the 10 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Visa Services, Power Engine and Pharma Stocks?
Visa services, power engine and pharma stocks are listed companies that provide visa, passport and citizen services for governments, build engines, generators and power solutions for industry and buildings, and develop and sell medicines for hospitals and pharmacies. Their earnings depend on international travel, power equipment demand and prescription demand.
Visa Services, Power Engine and Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| BLS International Services | 222.01 | 8,908 | 12.0 | 17.6 | 27.9 | 0.17 |
| Cummins India | 4,135.2 | 127,515 | 53.9 | 44.4 | 27.9 | 0.00 |
| Emcure Pharmaceuticals | 2,216.2 | 33,487 | 32.9 | 36.0 | 18.7 | 0.31 |
On valuation, BLS International Services and Emcure Pharmaceuticals trade at a P/E below the industry P/E, while Cummins India trades above it, which reflects the growth the market already expects. Readers comparing visa services, power engine and pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in visa services, power engine and pharma stocks can use the coming numbers to test whether growth is holding.
Why Do Visa Services, Power Engine and Pharma Stocks Have a Strong Roadmap in India?
Visa services, power engine and pharma stocks have a strong roadmap in India because rising international travel, strong demand for backup and prime power and steady growth in medicine sales keep widening the market for these companies.
- Visa services. More travellers apply for visas each year.
- Power engines. Data centres and plants need reliable power.
- Pharma. Hospitals and pharmacies stock more medicines.
Why BLS International Services Features Among These Visa Services, Power Engine and Pharma Stocks
Among the visa services, power engine and pharma stocks on this list, BLS International Services provides visa, passport and consular outsourcing services for governments and also runs digital, e-governance and banking correspondent services.
In the June 2026 quarter, revenue grew 24.1% year on year to Rs 913 crore, while net profit rose 11.4% to Rs 202 crore. Revenue rose from Rs 865 crore in FY22 to Rs 3,093 crore in FY26, a compound annual growth rate of 37.5%.
Net profit grew from Rs 111 crore in FY22 to Rs 724 crore in FY26, which works out to a compound annual growth rate of 59.7%. The company has a return on equity of 27.9%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 8,908 crore. The stock trades at a P/E of 12.0, below the industry P/E of 17.6.
Roadmap: The company is adding government mandates in many countries and widening its digital and citizen services. Rising international travel supports demand for visa and consular support.
What to watch: Follow new government mandates, travel demand and progress in digital services.
Why Cummins India Features Among These Visa Services, Power Engine and Pharma Stocks
Among the citizen services, generator and medicine shares on this list, Cummins India makes diesel and natural gas engines, generator sets, filtration products and power systems for infrastructure, data centres and industrial customers, and it also exports.
The company has a return on equity of 27.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 127,515 crore. The stock trades at a P/E of 53.9, above the industry P/E of 44.4.
Revenue rose from Rs 6,414 crore in FY22 to Rs 12,661 crore in FY26, a compound annual growth rate of 18.5%. Net profit grew from Rs 934 crore in FY22 to Rs 2,362 crore in FY26, which works out to a compound annual growth rate of 26.1%. In the June 2026 quarter, revenue grew 17.2% year on year to Rs 3,563 crore, while net profit rose 0.9% to Rs 609 crore.
Roadmap: The company benefits from demand for backup power at data centres, infrastructure projects and industrial plants, and it is widening its export base. A debt-free balance sheet supports capacity additions and new product lines.
What to watch: Track demand from data centres and new infrastructure and the growth of exports.
Why Emcure Pharmaceuticals Features Among These Visa Services, Power Engine and Pharma Stocks
Among the three companies on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.
Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%.
In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0.
Roadmap: It is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
What to watch: Look at the growth of the India branded business and the pace of new launches abroad.
BLS International Services vs Cummins India vs Emcure Pharmaceuticals on Key Financials
The table below sets the three visa services, power engine and pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| BLS International Services | 865 | 3,093 | 37.5% | 724 | 23.4% |
| Cummins India | 6,414 | 12,661 | 18.5% | 2,362 | 18.7% |
| Emcure Pharmaceuticals | 5,919 | 9,335 | 12.1% | 941 | 10.1% |
BLS International Services posts the highest return on equity in this group at 27.9%. Cummins India has the largest FY26 revenue at Rs 12,661 crore, and BLS International Services shows the fastest revenue growth with a 37.5% compound annual rate. A useful habit with visa services, power engine and pharma stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several visa outsourcing, diesel engine and branded generics stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| BLS International Services | 736 | 913 | 24.1% |
| Cummins India | 3,041 | 3,563 | 17.2% |
| Emcure Pharmaceuticals | 2,104 | 2,583 | 22.7% |
Key Risks to Check Before Investing in Visa Services, Power Engine and Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these visa services, power engine and pharma stocks, the main points are: Long-term citizen services, generator and medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Travel cycles. Bookings and occupancy follow travel demand.
- Capital spending cycles. Customer investment in plants and equipment can vary.
- Pricing pressure. Generic prices can change by market.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter visa services, power engine and pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Visa Services, Power Engine and Pharma Stocks
Visa services, power engine and pharma stocks reward patient research into demand, execution and financial strength. BLS International Services, Cummins India and Emcure Pharmaceuticals each have a clear plan to grow. Based on the 10 November 2026 close, BLS International Services trades at Rs 222.01, Cummins India at Rs 4,135.2 and Emcure Pharmaceuticals at Rs 2,216.2. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these visa services, power engine and pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track visa services, power engine and pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are visa services, power engine and pharma stocks?
Ans. Visa services, power engine and pharma stocks are listed companies that provide visa, passport and citizen services for governments, build engines, generators and power solutions for industry and buildings, and develop and sell medicines for hospitals and pharmacies. Their earnings depend on international travel, power equipment demand and prescription demand. This list looks at three of them, BLS International Services, Cummins India and Emcure Pharmaceuticals, using reported FY22 to FY26 financials and the 10 November 2026 closing prices.
Which visa services, power engine and pharma stocks are covered in this list?
Ans. This list covers BLS International Services, Cummins India and Emcure Pharmaceuticals. Based on the 10 November 2026 close, BLS International Services traded at Rs 222.01, Cummins India at Rs 4,135.2 and Emcure Pharmaceuticals at Rs 2,216.2. Their return on equity ranges from 18.7% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.1% to 37.5%.
Why do visa services, power engine and pharma stocks have a strong future roadmap in India?
Ans. Visa services, power engine and pharma stocks have a strong roadmap in India because rising international travel, strong demand for backup and prime power and steady growth in medicine sales keep widening the market for these companies. The main drivers are as follows. Visa services. More travellers apply for visas each year. Power engines. Data centres and plants need reliable power. Pharma. Hospitals and pharmacies stock more medicines. Together these factors give the companies on this list a visible path for growth over the coming years.
How has BLS International Services performed financially?
Ans. Revenue rose from Rs 865 crore in FY22 to Rs 3,093 crore in FY26, a compound annual growth rate of 37.5%. Net profit grew from Rs 111 crore in FY22 to Rs 724 crore in FY26, which works out to a compound annual growth rate of 59.7%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 913 crore, while net profit rose 11.4% to Rs 202 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 8,908 crore. The stock trades at a P/E of 12.0, below the industry P/E of 17.6. Looking ahead, the company is adding government mandates in many countries and widening its digital and citizen services. Rising international travel supports demand for visa and consular support.
How has Cummins India performed financially?
Ans. Revenue rose from Rs 6,414 crore in FY22 to Rs 12,661 crore in FY26, a compound annual growth rate of 18.5%. Net profit grew from Rs 934 crore in FY22 to Rs 2,362 crore in FY26, which works out to a compound annual growth rate of 26.1%. In the June 2026 quarter, revenue grew 17.2% year on year to Rs 3,563 crore, while net profit rose 0.9% to Rs 609 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 127,515 crore. The stock trades at a P/E of 53.9, above the industry P/E of 44.4. Looking ahead, the company benefits from demand for backup power at data centres, infrastructure projects and industrial plants, and it is widening its export base. A debt-free balance sheet supports capacity additions and new product lines.
How has Emcure Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
What risks should investors check before buying visa services, power engine and pharma stocks?
Ans. Investors should check a few risks before buying visa services, power engine and pharma stocks. Travel cycles. Bookings and occupancy follow travel demand. Capital spending cycles. Customer investment in plants and equipment can vary. Pricing pressure. Generic prices can change by market. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of visa services, power engine and pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 10 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
